Eli Lilly's $3 Billion "Heavy Bet" on China

Why is Eli Lilly investing in China’s supply chain?

Recently, Eli Lilly announced plans to invest a total of $3 billion over the next ten years to expand its supply chain capacity in China.

According to the plan, the $3 billion investment will follow a “internal expansion + external cooperation” dual-track approach: on one hand, leveraging Suzhou factory’s technological and talent advantages to strengthen the capacity for intestinally active insulin injections; on the other hand, adding oral solid dosage production capacity in Beijing and collaborating with multiple local manufacturing partners to release additional capacity.

As a key move in this round of investment, Eli Lilly also announced a strategic partnership with leading local CDMO Kanglong Chem, investing $200 million initially to support its technological development, with plans to gradually expand the scale based on future growth. This news immediately drove Kanglong Chem’s stock price up more than 8% during the trading day in A-shares and over 13% in H-shares at one point.

To date, Eli Lilly’s total investment in China has approached $6 billion, covering the expansion of the Suzhou manufacturing base, the China Medical Innovation Center, and innovation incubators in Beijing and Shanghai, among other strategic hubs.

The core target of this investment is Eli Lilly’s first registered oral small-molecule GLP-1 receptor agonist, orforglipron. By the end of 2025, Eli Lilly China has submitted a marketing application to the National Medical Products Administration (NMPA) for this drug to treat type 2 diabetes and obesity, which is currently under review.

The strategic significance of this layout is self-evident. By 2025, Eli Lilly’s injectable dual-target drug tirzepatide will top global sales at $36.507 billion, earning it the title of “pharmaceutical king.” However, the fear of injections, cold chain storage requirements, and inconvenience of travel have long been barriers to patient adherence. As an oral alternative, orforglipron aims to lower treatment barriers, especially for patients who prefer oral medication or live in areas with inadequate cold chain infrastructure.

The Chinese market’s potential is a key driving force. Statistics show that China has approximately 148 million people with type 2 diabetes, and over 500 million adults are affected by overweight or obesity, making it one of the world’s major markets for metabolic disease treatment. As the approval process for orforglipron advances, a fierce competition for production capacity and market penetration for oral weight-loss drugs has just begun.

Analysts point out that this move signifies Eli Lilly’s positioning of China as a critical node in the global supply chain. China is shifting from the world’s largest consumer market to an important base for innovation and manufacturing capacity. Through joint development with local companies in cutting-edge technologies such as oral solid formulations and continuous manufacturing, the technological level of domestic CDMO companies will be substantially enhanced, enabling them to participate in higher value-added global pharmaceutical manufacturing divisions.

Eli Lilly pipeline and competitive advantages

Source: Yaozhi Data - Global Drug Analysis System

Conclusion: Behind the $3 billion investment is a century-long game of weight management and a strategic migration under the geopolitical economic landscape. As the global race for GLP-1 accelerates, choosing China as a production hub is not only a vote for China’s pharmaceutical innovation ecosystem but also a reshaping of global supply chain resilience. With the countdown to orforglipron approval underway, a new era of cross-border pharmaceutical joint ventures in China is gradually unfolding.

Reference sources:

1. Yaozhi Data - Global Drug Analysis System

Disclaimer: This content is for industry information dissemination only and does not represent Yaozhi’s position.